These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 29119932)

  • 1. Relevance of CYP2C9 Function in Valproate Therapy.
    Monostory K; Nagy A; Tóth K; Bűdi T; Kiss Á; Déri M; Csukly G
    Curr Neuropharmacol; 2019; 17(1):99-106. PubMed ID: 29119932
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical significance of CYP2C9-status guided valproic acid therapy in children.
    Bűdi T; Tóth K; Nagy A; Szever Z; Kiss Á; Temesvári M; Háfra E; Garami M; Tapodi A; Monostory K
    Epilepsia; 2015 Jun; 56(6):849-55. PubMed ID: 25967074
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Associations of CYP2C9 and CYP2A6 Polymorphisms with the Concentrations of Valproate and its Hepatotoxin Metabolites and Valproate-Induced Hepatotoxicity.
    Zhao M; Zhang T; Li G; Qiu F; Sun Y; Zhao L
    Basic Clin Pharmacol Toxicol; 2017 Aug; 121(2):138-143. PubMed ID: 28273397
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phenoconversion of CYP2C9 in epilepsy limits the predictive value of CYP2C9 genotype in optimizing valproate therapy.
    Tóth K; Bűdi T; Kiss Á; Temesvári M; Háfra E; Nagy A; Szever Z; Monostory K
    Per Med; 2015 Jun; 12(3):199-207. PubMed ID: 29771647
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factors Influencing Plasma Concentrations of Valproic Acid in Pediatric Patients With Epilepsy and the Clinical Significance of CYP2C9 Genotypes in Personalized Valproic Acid Therapy.
    Ma B; Yang K; Li X; Su N; Yu T; Zou Y; Xu X; Wang F; Cheng J; Yan Z; Chen T; Zhang L
    Ther Drug Monit; 2024 Aug; 46(4):503-511. PubMed ID: 38287884
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of uridine diphosphate glucuronosyltransferase 2B7 -161C>T polymorphism on the concentration of valproic acid in pediatric epilepsy patients.
    Inoue K; Suzuki E; Yazawa R; Yamamoto Y; Takahashi T; Takahashi Y; Imai K; Koyama S; Inoue Y; Tsuji D; Hayashi H; Itoh K
    Ther Drug Monit; 2014 Jun; 36(3):406-9. PubMed ID: 24365988
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical relevance of genetic polymorphism in CYP2C9 gene to pharmacodynamics and pharmacokinetics of phenytoin in epileptic patients: validatory pharmacogenomic approach to pharmacovigilance.
    Kousar S; Wafai ZA; Wani MA; Jan TR; Andrabi KI
    Int J Clin Pharmacol Ther; 2015 Jul; 53(7):504-16. PubMed ID: 25943175
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of CYP2C9, CYP2A6, ACSM2A, and CPT1A gene polymorphisms with adverse effects of valproic acid in Chinese patients with epilepsy.
    Wang C; Wang P; Yang LP; Pan J; Yang X; Ma HY
    Epilepsy Res; 2017 May; 132():64-69. PubMed ID: 28315807
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of
    Ramakrishnan K; Kesavan R; Venkatraman S; Narayan SK; Kumar RR; Shewade D
    Per Med; 2023 Sep; 20(5):417-424. PubMed ID: 37811569
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacogenetic Variants and Plasma Concentrations of Antiseizure Drugs: A Systematic Review and Meta-Analysis.
    Milosavljevic F; Manojlovic M; Matkovic L; Molden E; Ingelman-Sundberg M; Leucht S; Jukic MM
    JAMA Netw Open; 2024 Aug; 7(8):e2425593. PubMed ID: 39115847
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Frequencies of CYP2C9 polymorphisms in North Indian population and their association with drug levels in children on phenytoin monotherapy.
    Chaudhary N; Kabra M; Gulati S; Gupta YK; Pandey RM; Bhatia BD
    BMC Pediatr; 2016 May; 16():66. PubMed ID: 27179628
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of age, gender and CYP2C9/2C19 genotypes on dose-adjusted steady-state serum concentrations of valproic acid-a large-scale study based on naturalistic therapeutic drug monitoring data.
    Smith RL; Haslemo T; Refsum H; Molden E
    Eur J Clin Pharmacol; 2016 Sep; 72(9):1099-104. PubMed ID: 27353638
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early post-traumatic seizures are associated with valproic acid plasma concentrations and UGT1A6/CYP2C9 genetic polymorphisms in patients with severe traumatic brain injury.
    Sun Y; Yu J; Yuan Q; Wu X; Wu X; Hu J
    Scand J Trauma Resusc Emerg Med; 2017 Aug; 25(1):85. PubMed ID: 28841884
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of CYP2C9 and CYP2A6 on plasma concentrations of valproic acid: a meta-analysis.
    Yoon HY; Ahn MH; Yee J; Lee N; Han JM; Gwak HS
    Eur J Clin Pharmacol; 2020 Aug; 76(8):1053-1058. PubMed ID: 32385545
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of uridine diphosphate glucuronosyltransferase (UGT)1A6 genetic polymorphism on valproic acid pharmacokinetics in Indian patients with epilepsy: a pharmacogenetic approach.
    Munisamy M; Tripathi M; Behari M; Raghavan S; Jain DC; Ramanujam B; Arumugam K; Rajakannan T; Mallayasamy SR; Subbiah V
    Mol Diagn Ther; 2013 Oct; 17(5):319-26. PubMed ID: 23749495
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of
    Zheng XX; You YX; Zhao LL; Du Y; Xu SQ; Tang DQ
    Pharmacogenomics; 2023 Feb; 24(3):153-162. PubMed ID: 36718958
    [No Abstract]   [Full Text] [Related]  

  • 17. Inhibitory effect of valproic acid on cytochrome P450 2C9 activity in epilepsy patients.
    Gunes A; Bilir E; Zengil H; Babaoglu MO; Bozkurt A; Yasar U
    Basic Clin Pharmacol Toxicol; 2007 Jun; 100(6):383-6. PubMed ID: 17516991
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CYP2C9 polymorphisms and phenytoin metabolism: implications for adverse effects.
    Franco V; Perucca E
    Expert Opin Drug Metab Toxicol; 2015; 11(8):1269-79. PubMed ID: 26037375
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic Polymorphism of Drug-Metabolizing Enzymes CYP2C9 and CYP2C19 in Moroccan Population.
    Afilal D; Basselam MA; Brakez Z; Chouham S; Brehm A; Izaabel EH
    Genet Test Mol Biomarkers; 2017 May; 21(5):298-304. PubMed ID: 28282224
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differences in CYP2C9 Genotype and Enzyme Activity Between Swedes and Koreans of Relevance for Personalized Medicine: Role of Ethnicity, Genotype, Smoking, Age, and Sex.
    Hatta FH; Lundblad M; Ramsjo M; Kang JH; Roh HK; Bertilsson L; Eliasson E; Aklillu E
    OMICS; 2015 Jun; 19(6):346-53. PubMed ID: 25977991
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.